PD1 and PARP for Maintenance Therapy in NSLLC

NCT05392686 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: PD-1 inhibitor
DRUG: PARP inhibitor

Sponsor

Tianjin Medical University Cancer Institute and Hospital